ADAM10 Antibody #14194
- WB
- IP
Inquiry Info. # 14194
Please see our recommended alternatives.
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 68, 90 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
ADAM10 Antibody recognizes endogenous levels of total ADAM10 protein, including the active, mature 68 kDa protein and the 90 kDa precursor chain. The antibody also recognizes a 35 kDa protein of unknown origin.
Species Reactivity:
Human
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ADAM10 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Members of the ADAM (a disintegrin and a metalloprotease) family of multidomain membrane proteins influence cell signaling and adhesion by shedding cell surface proteins, such as cytokines and growth factors. This process influences cell-extracellular matrix (ECM) adhesion and ECM remodeling. Conserved domains found in most ADAM family proteins include a prodomain, a zinc-dependent metalloprotease domain, a disintegrin domain, a carboxy-terminal cysteine-rich domain, an EGF-like sequence, and a short cytoplasmic tail (1,2).
The ADAM metallopeptidase domain 10 (ADAM10) is a plasma membrane proteinase that cleaves membrane-bound proteins targeted for regulated intramembrane proteolysis (RIP). The ADAM10 prodomain acts as a chaperone that stabilizes mature ADAM protein folding, and prevents target-protein shedding through inhibition of ADAM10 proteinase activity (3,4). Mature ADAM10 is the major α-secretase responsible for cleavage of Notch, APP, cadherins, and prion protein (5-7). The ADAM10 protein cleaves receptor tyrosine kinases and their associated ligands and displays a wide range of regulatory functions across related signaling pathways (8). Research studies using knockout mice demonstrate that loss of ADAM10 results in defects in cortex formation, lymphocyte development, and cardiovascular development (9-11). Increased ADAM10 protein expression correlates with progression of many types of cancer (i.e. gastric cancer, hepatocellular carcinoma, and brain glioma), due to increased cancer cell migration, metastasis, and invasion (12-14). Mutations in the corresponding ADAM10 gene result in a rare, autosomal dominant pigmentation disorder known as reticulate acropigmentation of Kitamura (15).
- Turner, A.J. and Hooper, N.M. (1999) Biochem Soc Trans 27, 255-9.
- Edwards, D.R. et al. (2008) Mol Aspects Med 29, 258-89.
- Suh, J. et al. (2013) Neuron 80, 385-401.
- Moss, M.L. et al. (2007) J Biol Chem 282, 35712-21.
- Hartmann, D. et al. (2002) Hum Mol Genet 11, 2615-24.
- Miller, M.A. et al. (2013) Proc Natl Acad Sci U S A 110, E2074-83.
- Reiss, K. et al. (2005) EMBO J 24, 742-52.
- Endres, K. et al. (2009) Neurobiol Dis 36, 233-41.
- Jorissen, E. et al. (2010) J Neurosci 30, 4833-44.
- Zhang, C. et al. (2010) Dev Dyn 239, 2594-602.
- Gibb, D.R. et al. (2011) Mol Immunol 48, 1319-27.
- Wang, Y.Y. et al. (2011) J Surg Oncol 103, 116-23.
- Yuan, S. et al. (2013) Oncol Rep 30, 1715-22.
- Bulstrode, H. et al. (2012) Cancer Lett 326, 79-87.
- Kono, M. et al. (2013) Hum Mol Genet 22, 3524-33.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.